Ulocuplumab manufacturers
- Ulocuplumab
-
- $645.00
-
2026-07-27
- CAS:1375830-34-4
- Purity: 97.5% (SDS-PAGE); 96.2% (SEC-HPLC)
- Supply Ability: 10g
|
| | Ulocuplumab Basic information |
| Product Name: | Ulocuplumab | | Synonyms: | Ulocuplumab;Research Grade Ulocuplumab(DHF39901);Ulocuplumab (anti-CXCR4);BMS 936564|||MDX 1338;Research Grade Ulocuplumab | | CAS: | 1375830-34-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Ulocuplumab Structure]() |
| | Ulocuplumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Ulocuplumab Usage And Synthesis |
| Uses | Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models[1][2]. | | in vivo | Ulocuplumab (3-30 mg/kg; i.p.; every 3-4 days for 5 doses; 65 days in total) inhibits tumor growth of multiple myeloma xenograft models in mice, including Ramos B cells, HL-60 cells, MOLP-8 cells, Nomo-1 cells, and JJN-3R cells models[1].
| Animal Model: | Severe combined immunodeficient (SCID) mice of AML model (MOLP-8 cells)[1] | | Dosage: | 3-30 mg/kg | | Administration: | Intraperitoneal injection; every 3-4 days for 5 doses; last for 65 days | | Result: | Significantly delayed mean tumor growth by 66% and 56% when compared with isotype control on day 25. |
| | IC 50 | CXCR4 | | References | [1] Kashyap MK, et al. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19;7(3):2809-22. DOI:10.18632/oncotarget.6465
[2] Kuhne MR, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66. DOI:10.1158/1078-0432.CCR-12-2333 |
| | Ulocuplumab Preparation Products And Raw materials |
|